A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity

Obesity Reviews

Volumn 13, Issue 6, 2012, Pages 483-498

  Gray, L J ^a   Cooper, N ^a   Dunkley, A ^a   Warren, F C ^a   Ara, R ^b   Abrams, K ^a   Davies, M J ^a   Khunti, K ^a   Sutton, A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Meta analysis; Orlistat; Rimonabant; Sibutramine

Indexed keywords

RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ARTICLE; BODY MASS; DRUG DOSE INCREASE; DRUG EFFICACY; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; OBESITY; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; BODY MASS INDEX; CYCLOBUTANES; HUMANS; LACTONES; LIFE STYLE; OBESITY; PIPERIDINES; PYRAZOLES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84860881560     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/j.1467-789X.2011.00981.x     Document Type: Article

References (32)

1. World Health Organization Global Infobase. Obesity and overweight fact sheet September 2006. [WWW document]. URL: (accessed January 2011). 2011 [updated February 2010].
2. Wang CL, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 815-825.
3. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
4. Wing RR, Lang W, Wadden TA etal. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-1486.
5. Brunner E, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007; (4): CD002128.
6. Sjöström CD, Lystig T, Lindroos AK. Impact of weight change, secular trends and ageing on cardiovascular risk factors: 10-year experiences from the SOS study. Int J Obes 2011; 35: 1413-1420.
7. Johnson WD, Brashear MM, Gupta AK, Rood DH, Ryan DH. Incremental weight loss improves cardiometabolic risk in extremely obese adults. Am J Med 2011; 124: 931-938.
8. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
9. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504.
10. National Institute for Clinical Excellence. Surgical and pharmacological intreventions for obesity. 2010.
11. National Institute of Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. Full guideline reference CG43. [WWW document]. URL: (accessed January 2011). 2006.
12. Padwal R, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007; 369: 71-77.
13. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
14. Johansson K, Neovius K, DeSantis SM, Rössner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev 2009; 10: 564-575.
15. European Medicines Agency. [WWW document]. URL (accessed January 2011).
16. European Medicines Agency. [WWW document]. URL (accessed January 2011).
17. James WPT, Caterson ID, Coutinho W etal. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
18. Cahoon L. Companies throw their weight behind new antiobesity drugs. Nat Med 2010; 16: 136.
19. Klonoff DC, Greenway F. Drugs in the pipeline for the obesity market. J Diabetes Sci Technol 2008; 2: 913-918.
20. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51-68.
21. LeBlanc ES, O'Connoe E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevent treatments for obesity in adults: a systematic review for the U.S. Preventative Services Task Force. Ann Intern Med 2011; 155: 434-477.
22. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
23. Jadad AR, Moore A, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
24. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
25. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell: Chichester, 2008.
26. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. 2005;BMJ 331: 897-900.
27. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. [WWW document]. URL (accessed January 2011). 2011.
28. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS Version 1.4 User Manual. Cambridge MRC Biostatistics Unit. 2003.
29. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009; 28: 1861-1881.
30. Dansinger ML, Tatsioni A, Wong JB, Chung M, Balk E. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med 2007; 147: 41-50.
31. Christensen R, Kristensen PK, Bartels EM etal. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706-1713.
32. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta analysis of controlled tirlas, empirical study. Int J Epidemiol 2002; 31: 115-123.